trapelo IN THE NEWS
Read what others around the country are reporting about us
March 3, 2020 | OncLive
Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer
Lori Brisban, VP of precision medicine at Texas Oncology talks about the ovarian cancer beta trial they are conducting with community oncologists and how Trapelo is helping one of the largest oncology practices in the U.S. standardize molecular testing guidelines.
July 14, 2020 | Managed Healthcare Executive
It's Possible for Those Who Practice, Pay for Precision Oncology to Catch Up to Speed of Innovation
In this article, Dr. Lee Newcomer shares his opinion on the state of precision oncology.
The fast-evolving field of precision medicine offers the promise of more effective treatments and better outcomes, and it’s time that we collaborate to keep outdated clinical and reimbursement practices from slowing it down. Only when everyone is aligned around what’s most appropriate for the patient, will consistent, value-based precision oncology be possible.
February 23, 2020 | OncLive
Dr. Paulson on the Importance of Biomarker Testing in Oncology
R. Steven Paulson, MD, physician, president and chairman at Texas Oncology, discusses the importance of molecular testing in the era of precision medicine in oncology.
January 17, 2020 | OncLive
Utility of Trapelo to Increase Molecular Testing Rates
Lori Brisban, VP of precision medicine at Texas Oncology, talks about how Trapelo helps oncologists keep up-to-date with the latest guidelines and know which molecular test is the right test for the right patient and the right tumor type.
October 2, 2019 | OncLive
Technology Advances Aid Treatment Decisions for Community Oncologists
Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.
For example, Trapelo is a novel single-technology platform with the ability to automatically update with treatment guidelines from the National Comprehensive Cancer Network (NCCN) and more to assist community oncologists with deciding on the optimal therapeutic path for their patients, explained Lori Brisbin.
“Only 30% of patients are being tested for precision medicine. If we don't test…then that is not a treatment option for them,” said Brisbin, vice president of precision medicine at Texas Oncology. “[The goal of Trapelo] is to advise on whom to test.”
In an interview during the 2019 OncLive® State of the Science Summit™ on Precision Medicine, Brisbin discussed using these types of technology platforms in precision medicine as well as the role of liquid biopsies.
August 12, 2019 | BioWorld MedTech
Data seen as replacing policy as coverage tool for precision medicine
The era of big data might still be in its infancy, but payers are already dealing with a deluge of bits and bytes that threatens to overwhelm their ability to keep up with recent developments in medical science. Clynt Taylor, CEO of Intervention Insights Inc., of Burlington, Mass., told BioWorld MedTech that payers are starting to see the light when it comes to reacting to data that suggest a shift in coverage policy, but that over time, payers will replace those fixed policies with a data-driven approach that adapts to patients' needs in real time.
July, 2019 | HIT Like A Girl Podcast
An interview with Janine Morales, PhD, Senior Director Clinical Knowledge Systems
In this podcast, Janine Morales, PhD of Intervention Insights shares her career path as a woman in Health IT and how her company’s real-time, evidence-supported technology platform helps oncologists, practices, molecular labs, and payers make the most appropriate decisions for cancer patients.
July 26, 2019 | Healthcare IT News
Physicians are key to making precision medicine investments pay off
As the practice of tailoring technology-driven treatment plans for each patient takes hold, physicians are being asked to make more specific decisions than ever before.
Finding the best care for a patient can be a constantly moving target. The number of stakeholders, the constant advance of new information and treatment options and the nuanced demands of different payers make for a maze of complexities to navigate. In the field of oncology, for example, nobody but a specialist could be expected to keep up with the growing wealth of knowledge in the treatment of individual cancers.
Yet most patients are treated by general oncologists who may not be abreast of every best course of action for specific conditions. These practices might not know which treatments a patient could be pre-approved for, or which payers are most likely to compensate and for what. As the practice of tailoring precision medicine plans for each patient takes hold, physicians are being asked to make more specific treatment decisions than ever before.
"You have labs, you have payers, you have providers and you have pharma – and they’re all interested in what the doctor is about to do with a patient," said Clynt Taylor, CEO of Intervention Insights, which makes a tool called Trapelo that helps streamline treatment and payment options.
June 21, 2019 | American Journal of Managed Care
Removing the Barriers to Improve the Use of Diagnostic Tests for Precision Cancer Care
Currently, the number of patients who are actually utilizing precision cancer care treatments is small, but it is growing fast. As that happens, physicians will need to get comfortable with ordering the right tests, explained Clynt Taylor, chief executive officer of Intervention Insights, and Lee Newcomer, MD, formerly of UnitedHealth Group.